XML 148 R21.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

Share capital | 12 Months Ended
--- | ---
Dec. 31, 2019
Equity [Abstract] |
Share capital | The following table presents a summary of the common shares issued and outstanding as of and for the years ended December 31, 2019, 2018 and 2017:
Common shares | 2019 |  | 2018 |  | 2017
Common shares issued, beginning of period | 93,639,610 |  |  | 107,227,347 |  |  | 106,501,299 |
Options exercised | 187,678 |  |  | — |  |  | 150,802 |
Restricted shares granted, net of forfeitures | 366,453 |  |  | 50,644 |  |  | (35,011 | )
Performance restricted shares granted, net of forfeitures and shares withheld | 31,757 |  |  | 256,106 |  |  | 610,257 |
Retirement of treasury shares and shares repurchased (1) | — |  |  | (14,256,043 | ) |  | — |
Warrants exercised, net (2) | — |  |  | 361,556 |  |  | — |
Common shares issued, end of period | 94,225,498 |  |  | 93,639,610 |  |  | 107,227,347 |
Treasury shares, end of year | — |  |  | — |  |  | (3,944,920 | )
Common shares outstanding, end of year | 94,225,498 |  |  | 93,639,610 |  |  | 103,282,427 |
(1) | Prior to December 31, 2017, common shares repurchased by the Company were not canceled and were classified as treasury shares. Effective January 1, 2018, all treasury shares were retired and subsequent shares repurchased are retired.
(2) | During the year ended December 31, 2018, 1,156,184 warrants were exercised. As a result of the warrant holder electing net settlement, 794,628 of those common shares were withheld by the Company and were subsequently retired, resulting in a net issuance of 361,556 common shares.
Authorized and issued The Company’s authorized share capital of $33.0 million is comprised of 300,000,000 common shares with a par value of $0.10 each and 30,000,000 preference shares with a par value of $0.10 each. No preference shares have been issued to date. Share repurchases On May 4, 2016, the Company’s Board of Directors authorized a common share repurchase program for up to an aggregate of $100.0 million of the Company’s outstanding common shares. On February 28, 2018, the Company’s Board of Directors authorized the repurchase of an additional $148.3 million of common shares, which together with the shares remaining under the previously announced share repurchase program, would allow the Company to repurchase up to $200.0 million more of the Company’s outstanding common shares in the aggregate. Under the common share repurchase program, the Company may repurchase shares from time to time in privately negotiated transactions or in open-market purchases in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Securities Exchange Act of 1934, as amended. During the year ended December 31, 2019, the Company did not repurchase any of its common shares. During the year ended December 31, 2018, the Company repurchased 10,311,123 of its common shares in the open market for an aggregate cost of $138.7 million at a weighted average cost, including commissions, of $13.45 per share. Common shares repurchased by the Company during the year ended December 31, 2018 were retired. In addition, the Company also retired all shares previously held in treasury. As of December 31, 2019, the Company is authorized to repurchase up to an aggregate of $61.3 million of additional common shares under its share repurchase program. Warrants The Company’s Founders and an advisor provided insurance industry expertise, resources and relationships to ensure that the Company would be fully operational with key management in place in time for the January 2012 underwriting season. In consideration of these commitments, the Company reserved for issuance to the Founders and an advisor warrants to purchase, in the aggregate, up to 4.0% (Founders 3.5% and an advisor 0.5%) of the diluted shares (up to a maximum of $1 billion of subscribed shares) provided that the Founders and the advisor will not be issued any warrants for common shares issued in consideration for any capital raised by the Company in excess of $1 billion. The following is a summary of warrants as of December 31, 2019:
| Exercise price |  | Authorized and issued |  | Aggregated fair value of warrants
Founders | $ | 10.00 |  |  | 2,913,684 |  |  | $ | 10,884 |
Advisor | $ | 10.00 |  |  | 581,295 |  |  | 2,171 |
|  |  | 3,494,979 |  |  | $ | 13,055 |
The warrants expire 10 years from the date of issuance, December 22, 2011, and will be exercisable at a price per share of $10.00, which is equal to the price per share paid by investors in the initial private offering.

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI http://asc.fasb.org/topic&trid=2208762 + Details
Name: | us-gaap_StockholdersEquityNoteDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration